Pipeline updates and news over the previous week from 20 companies.

Aug 03, 2014 No Comments

Pacira Pharmaceuticals, Inc.(NASDAQ: PCRX) noted that the FDA has set a PDUFA date of March 5, 2015 for the supplemental New Drug Application (sNDA) for a nerve block indication for EXPAREL. NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) said that their BAYnovation trial for viral conjunctivitis has been completed and top-line results are due in mid-August 2014. Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) maintained guidance that the pre-planned […]

Read more

ACRX receives CRL. TSRO NDA filing due by early September + pipeline updates for GLMD ESPR

Jul 27, 2014 No Comments

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that the FDA has issued a Complete Response Letter (CRL) for the new drug application (NDA) for Zalviso. The CRL contains requests for additional information on the Zalviso System to ensure proper use of the device. Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) provided an update noting that Phase 2b interim data from their […]

Read more

EGRX FDA Approval. INO meets endpoint. INCY fails to meet endpoint.

Jul 24, 2014 No Comments

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) announced that the FDA has approved Ryanodex for injectable suspension indicated for the treatment of malignant hyperthermia (MH). Eagle has been informed by the FDA that it will learn over the next four to six weeks if it has been granted the seven year Orphan Drug market exclusivity. Incyte Corporation(Nasdaq: INCY) […]

Read more

PBYI releases positive Phase 3 data. LJPC offering. Trial updates for ATRS HALO

Jul 23, 2014 No Comments

Puma Biotechnology, Inc. (NYSE: PBYI) announced positive top line results from their Phase 3 clinical trial of PB272 (neratinib) for the extended adjuvant treatment of breast cancer (ExteNET Trial) in women with early stage HER2-positive breast cancer. The primary endpoint of the trial was disease free survival (DFS). The results of the trial demonstrated that treatment […]

Read more

Trial initiations and updates for TTNP RXDX GNCA DPRX SNTA

Jul 22, 2014 No Comments

Titan Pharmaceuticals, Inc. (TTNP.OB) announced enrollment of the first patients in the Phase 3 trial to support the resubmission of the New Drug Application (NDA) for Probuphine, for the maintenance treatment of opioid dependence. The study, which is expected to be completed by the middle of 2015, followed by their resubmission of the NDA in late 2015. […]

Read more

SGYP Phase 2 SP-333 data due 4Q + trial initiations for ASPX ISIS

Jul 18, 2014 1 Comment

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced that it has completed patient enrollment for its Phase 2 trial of SP-333, in patients with opioid-induced constipation (OIC). Top-line data are due 4Q 2014. Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX) announced the enrollment of the first patients in a pivotal Phase 2/3 trial of SD-809 (deutetrabenazine), for the treatment of tardive […]

Read more

SLXP Pharming FDA Approval. POZN receives Class 2 resubmission + GNCA RPRX news

Jul 17, 2014 No Comments

POZEN Inc. (NASDAQ: POZN) announced that the FDA has set a PDUFA date of December 30, 2014 for the Class 2 re-submission of the New Drug Application (NDA) for PA8140/PA32540. Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the initiation of a Phase 3 clinical program for fostamatinib, in patients with ITP (immune thrombocytopenic purpura). Results are expected at year-end 2015. Salix […]

Read more

TRGT fails Phase 2b. Positive news for SLXP PGNX EXEL. Phase 3 data due soon for ADHD ZSPH + AERI SGYP VTUS ANTH GNCA updates

Jul 15, 2014 No Comments

Targacept, Inc. (NASDAQ: TRGT) announced that it did not meet the primary endpoint in their Phase 2b monotherapy trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals(NASDAQ:PGNX) announced that the FDA has informed Salix that RELISTOR Subcutaneous Injection, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic […]

Read more

KYTH PDUFA date set. Offering details for TXNP ASPX

Jul 12, 2014 No Comments

KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced that the FDA has assigned a PDUFA date for their New Drug Application (NDA) of ATX-101 (deoxycholic acid) of May 13, 2015. The company also expects that an Advisory Committee meeting will also be held. Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced it will issue 657,000 shares of common stock at a price of […]

Read more